FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, specifically to the induction of an immune response against the alpha-3-domain polypeptide from Class I main histocompatibility complex (MIC) chain, and can be used in medicine for treatment of cancer whose cells express this polypeptide. A fusion protein is proposed, including a monomeric subunit of ferritin protein, which determines the ability of the specified fusion protein to self-assemble with the formation of nanoparticles, which is attached to the alpha3-domain protein from the MIC chain.
EFFECT: invention provides induction of high titers of antibodies against the alpha 3-domain.
12 cl, 11 ex, 21 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIGENIC POLYPEPTIDES BASED ON THE RESPIRATORY SYNCYTIAL VIRUS SEQUENCE | 2019 |
|
RU2807992C2 |
| ANTIGENIC POLYPEPTIDES BASED ON OSPA SEQUENCE | 2019 |
|
RU2816208C2 |
| BIOLOGICAL MATERIALS FOR MODULATING IMMUNE RESPONSES | 2017 |
|
RU2770060C2 |
| COMPOSITION FOR IMMUNOSTIMULATION AND USE THEREOF | 2020 |
|
RU2815763C1 |
| MODIFIED NON-NATURAL NKG2D LIGANDS WHICH SELECTIVELY DELIVER ATTACHED HETEROLOGOUS MOLECULES TO NON-NATURAL NKG2D RECEPTORS ON CAR CELLS | 2020 |
|
RU2823728C2 |
| PROTEIN AND VACCINE AGAINST SARS-CoV-2 INFECTION | 2020 |
|
RU2815060C1 |
| ADVANCED CORONAVIRUS VACCINE | 2022 |
|
RU2816182C2 |
| SUBUNIT VACCINE FOR TREATING OR PREVENTING RESPIRATORY TRACT INFECTION | 2020 |
|
RU2811991C2 |
| MESSENGER RNA VACCINES AGAINST WIDE RANGE OF CORONAVIRUS VARIANTS | 2022 |
|
RU2826172C2 |
| THERAPEUTIC ANTI-CANCER NEOEPITOPE VACCINE | 2017 |
|
RU2782422C2 |
